Ophthalmology – Tuberous Sclerosis Complex

What the Disorder Represents

Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem genetic disorder characterized by development of:

• Hamartomas
• Benign tumors
• Dysplastic lesions

in multiple organs, especially:

• Brain
• Skin
• Kidneys
• Heart
• Lungs
• Retina

It results from pathogenic variants affecting the:

TSC1–TSC2–mTOR signaling pathway.

⸻

Important Modern Terminology

The preferred name is:

Tuberous sclerosis complex

rather than simply “tuberous sclerosis.”

The historic triad of:

• Seizures
• “Adenoma sebaceum”
• Intellectual disability

is known as the Vogt triad, but it is:

Neither sensitive nor required for diagnosis.

Many patients do not have all three findings.

⸻

Important Modern Correction About Language

Older descriptions used:

• “Adenoma sebaceum”
• “Mental retardation”

Modern terminology is:

• Facial angiofibromas
• Intellectual disability

Facial angiofibromas are neither adenomas nor sebaceous lesions.

⸻

Genetic Basis

TSC results from pathogenic variants in:

• TSC1 on chromosome 9 → encodes hamartin
• TSC2 on chromosome 16 → encodes tuberin

Hamartin and tuberin form a complex that normally suppresses:

mTORC1 signaling.

Loss of this inhibitory pathway produces excessive:

• Cell growth
• Protein synthesis
• Proliferation
• Hamartoma formation

⸻

Why mTOR Is So Important

The central molecular abnormality is:

Overactivation of the mechanistic target of rapamycin pathway.

This explains why:

mTOR inhibitors such as everolimus and sirolimus

now have established therapeutic roles in TSC.

⸻

Inheritance Pattern

TSC is:

Autosomal dominant

with variable expression.

However, a large proportion of affected individuals represent:

De novo pathogenic variants

and therefore have no affected parent.

⸻

Genetic Testing – Major Modern Correction

Older sources stated that reliable genetic testing was unavailable.

This is now incorrect.

Modern molecular testing can identify a pathogenic variant in:

TSC1 or TSC2 in most patients with clinically definite TSC.

Genetic testing is useful for:

• Confirming diagnosis
• Family counseling
• Testing at-risk relatives
• Prenatal or reproductive counseling

A negative genetic test does not completely exclude TSC because mosaic or difficult-to-detect variants can occur.

⸻

Who Develops It

TSC occurs in all ethnic groups and both sexes.

Estimated birth incidence is roughly:

1 in 6,000–10,000 live births

although prevalence estimates vary.

Clinical severity ranges from:

• Very mild disease discovered incidentally
• Severe neurologic, renal, pulmonary, or developmental disease

⸻

Why the Phenotype Is So Variable

Even individuals within the same family may have very different manifestations.

Variation results from:

• Different pathogenic variants
• Mosaicism
• Second-hit somatic mutations
• Other genetic and environmental modifiers

Therefore genotype does not perfectly predict clinical severity.

⸻

Major Organ Systems Involved

TSC most commonly affects:

• Central nervous system
• Skin
• Kidneys
• Heart
• Lungs
• Retina
• Teeth/oral cavity
• Bone

It is therefore fundamentally a:

Multidisciplinary disease.

⸻

Neurologic Manifestations

Major neurologic abnormalities include:

• Cortical tubers
• Subependymal nodules
• Subependymal giant cell astrocytoma
• Epilepsy
• Infantile spasms
• Neurodevelopmental disorders

Seizures are among the most common and clinically important manifestations.

⸻

Cortical Tubers

Cortical and subcortical tubers are areas of:

• Abnormal cortical development
• Dysplastic neurons
• Giant cells
• Gliosis

They are strongly associated with:

Epilepsy and neurodevelopmental impairment.

⸻

Subependymal Nodules

Subependymal nodules occur along the walls of the lateral ventricles.

They may:

• Calcify
• Remain stable
• Occasionally evolve into or coexist with a subependymal giant cell astrocytoma (SEGA)

⸻

Subependymal Giant Cell Astrocytoma

SEGA typically develops near the:

Foramen of Monro

and can obstruct cerebrospinal fluid flow.

Potential consequences include:

• Hydrocephalus
• Headache
• Vomiting
• Papilledema
• Behavioral change
• Reduced consciousness

⸻

Ocular Relevance of Raised Intracranial Pressure

A patient with TSC and SEGA may develop:

Papilledema

if obstructive hydrocephalus occurs.

Papilledema in TSC is therefore usually a consequence of intracranial pressure, not a primary retinal manifestation.

⸻

Infantile Spasms

Infantile spasms are particularly important in TSC.

They may present with:

• Brief flexor spasms
• Extensor spasms
• Head nodding
• Clusters of repetitive movements

They require:

Prompt neurologic treatment.

⸻

First-Line Treatment of Infantile Spasms

In TSC-associated infantile spasms:

Vigabatrin is generally first-line therapy.

This is a major modern management point.

⸻

Ophthalmic Relevance of Vigabatrin

Vigabatrin can cause:

Permanent concentric visual-field loss

through retinal toxicity.

Risk relates particularly to:

• Cumulative exposure
• Duration of therapy

Children receiving vigabatrin require age-appropriate ophthalmic monitoring when feasible.

⸻

TSC-Associated Neuropsychiatric Disorders

The umbrella term:

TAND – TSC-associated neuropsychiatric disorders

includes:

• Intellectual disability
• Autism spectrum disorder
• ADHD
• Anxiety
• Mood disorders
• Behavioral difficulties
• Sleep problems
• Learning disorders

These manifestations are common but highly variable.

⸻

Characteristic Skin Findings

Cutaneous findings are often important diagnostic clues.

They include:

• Hypomelanotic macules
• Facial angiofibromas
• Shagreen patch
• Ungual/periungual fibromas
• Confetti skin lesions

⸻

Hypomelanotic Macules

These are often called:

Ash-leaf macules

because of their shape.

They may be present:

At birth or early infancy

and are often easier to detect with:

Wood lamp examination.

⸻

Facial Angiofibromas

Facial angiofibromas are:

• Reddish papules
• Frequently distributed over the nose and central face
• Often appearing during childhood

They were historically called:

Adenoma sebaceum, an outdated term.

⸻

Shagreen Patch

A shagreen patch is:

• Thickened
• Leathery
• Connective-tissue nevus-like plaque

often located over the:

Lumbosacral region.

⸻

Ungual Fibromas

Periungual or subungual fibromas:

• Develop around nails
• Are more common later in childhood or adulthood

These are also called:

Koenen tumors.

⸻

Major Ocular Manifestation

The classic eye lesion in TSC is:

Retinal astrocytic hamartoma.

These lesions may occur:

• On the optic disc
• Adjacent to the disc
• In the peripheral retina

They can be:

• Solitary
• Multiple
• Unilateral
• Bilateral

Multiple bilateral lesions strongly support TSC.

⸻

Retinal Astrocytic Hamartoma – Clinical Appearance

These lesions may appear as:

• Flat translucent retinal thickening
• Gray-white nodules
• Calcified “mulberry-like” masses

They often arise from the:

Retinal nerve fiber layer.

⸻

Traditional Morphologic Patterns

Three classic appearances are described:

Type 1

Relatively flat, smooth, semitranslucent lesion.

Type 2

Calcified, nodular:

“Mulberry” lesion

Type 3

Mixed characteristics.

These patterns may represent stages along a morphologic spectrum.

⸻

Optic Disc Involvement

Astrocytic hamartomas may arise:

• On the optic nerve head
• Immediately adjacent to it

They can resemble:

• Optic disc drusen
• Papilledema
• Other calcified lesions

Multimodal imaging helps clarify the diagnosis.

⸻

Optical Coherence Tomography

OCT may demonstrate:

• Hyperreflective retinal mass
• Distortion of retinal layers
• Calcification-related shadowing
• Intraretinal cystic change in exudative lesions

OCT is useful for:

• Baseline documentation
• Monitoring growth
• Detecting associated fluid

⸻

Fundus Autofluorescence

Calcified astrocytic hamartomas may demonstrate:

Hyperautofluorescence

although appearance varies according to:

• Calcification
• Pigment
• Overlying retina

⸻

B-Scan Ultrasonography

Larger calcified lesions may show:

• High internal reflectivity
• Acoustic shadowing

This can help distinguish heavily calcified hamartomas from other retinal masses.

⸻

Fluorescein Angiography

FA may show:

• Intrinsic tumor vasculature
• Late staining
• Leakage in more active or exudative lesions

Routine FA is unnecessary for asymptomatic stable lesions.

⸻

Retinal Hypopigmented Lesions

Some patients have:

Retinal achromic patches

which appear as hypopigmented retinal or RPE lesions.

These are recognized as a:

Minor diagnostic feature in modern criteria.

⸻

Are Retinal Hamartomas Usually Dangerous?

Most retinal astrocytic hamartomas are:

Stable and asymptomatic.

They often require:

Observation only.

⸻

Rare Ocular Complications

Occasionally, retinal astrocytic hamartomas may produce:

• Exudation
• Macular edema
• Serous retinal detachment
• Vitreous hemorrhage
• Retinal neovascularization
• Fibrosis
• Secondary glaucoma

Severe progressive ocular disease is uncommon.

⸻

Can Retinal Hamartomas Grow?

Yes, but substantial progression is uncommon.

Some lesions may:

• Slowly enlarge
• Become more calcified
• Develop exudation

Serial photography and OCT are useful when growth is uncertain.

⸻

Differential Diagnosis of Retinal Astrocytic Hamartoma

Important mimics include:

• Retinoblastoma
• Optic disc drusen
• Solitary retinal astrocytic hamartoma
• Myelinated retinal nerve fibers
• Toxocariasis
• Coats disease
• Other calcified retinal lesions

⸻

Distinguishing It From Retinoblastoma

This is particularly important in young children.

Retinoblastoma more commonly shows:

• True intraocular tumor mass
• Prominent calcification
• Subretinal or vitreous seeds
• Progressive growth
• Retinal detachment

TSC-associated astrocytic hamartomas are usually:

• Surface retinal lesions
• Relatively stable
• Often multiple or bilateral
• Associated with other TSC features

⸻

Solitary Retinal Astrocytic Hamartoma

An isolated retinal astrocytic hamartoma may occur in a patient without TSC.

Therefore:

One retinal astrocytic hamartoma does not automatically diagnose tuberous sclerosis complex.

The systemic context matters.

⸻

Cardiac Manifestations

The classic cardiac lesion is:

Rhabdomyoma.

These are often detected:

• Prenatally
• During infancy

They may cause:

• Arrhythmia
• Obstruction
• Heart failure

Many regress spontaneously during childhood.

⸻

Why Cardiac Rhabdomyoma Is a Diagnostic Clue

Multiple fetal or neonatal cardiac rhabdomyomas are strongly associated with:

TSC

and may prompt genetic evaluation before other manifestations become apparent.

⸻

Renal Manifestations

Major renal abnormalities include:

• Angiomyolipomas
• Renal cysts
• Chronic kidney disease

Rarely:

• Renal cell carcinoma

Renal disease is a major determinant of long-term morbidity.

⸻

Renal Angiomyolipoma

Angiomyolipomas consist of varying proportions of:

• Blood vessels
• Smooth muscle
• Fat

Large lesions may cause:

• Hemorrhage
• Flank pain
• Hematuria
• Renal impairment

⸻

Modern Treatment of Renal Angiomyolipoma

For enlarging or clinically significant TSC-associated angiomyolipoma:

mTOR inhibition with everolimus

is now an established treatment option.

Selective embolization is preferred for:

Acute hemorrhage.

Nephron-sparing approaches are favored whenever possible.

⸻

Pulmonary Manifestations

The major pulmonary complication is:

Lymphangioleiomyomatosis (LAM).

It occurs predominantly in:

Women after puberty.

⸻

Lymphangioleiomyomatosis

LAM produces abnormal proliferation of smooth-muscle-like cells leading to:

• Pulmonary cysts
• Dyspnea
• Pneumothorax
• Chylous effusion
• Progressive loss of lung function

Chest CT is much more sensitive than chest radiography.

⸻

Modern Treatment of LAM

Clinically significant LAM may be treated with:

Sirolimus

which can stabilize or improve pulmonary function.

Lung transplantation is reserved for severe end-stage disease.

⸻

Oral Findings

Oral manifestations may include:

• Dental enamel pits
• Gingival fibromas

These can support the diagnosis.

⸻

Bone Findings

Sclerotic bone lesions may occur, particularly in:

• Spine
• Pelvis
• Skull

They are often asymptomatic and usually do not require treatment.

⸻

Modern Diagnostic Framework

TSC is diagnosed using:

• Clinical criteria
• Molecular genetic criteria

A pathogenic variant in:

TSC1 or TSC2

can establish a molecular diagnosis.

⸻

Definite Clinical Diagnosis

A definite clinical diagnosis generally requires:

Two major features

or:

One major feature plus at least two minor features.

This basic structure remains clinically useful.

⸻

Major Diagnostic Features

Major features include:

• ≥3 hypomelanotic macules
• ≥3 facial angiofibromas or fibrous cephalic plaque
• ≥2 ungual fibromas
• Shagreen patch
• Multiple retinal hamartomas
• Cortical dysplasias
• ≥2 subependymal nodules
• SEGA
• Cardiac rhabdomyoma
• LAM
• ≥2 renal angiomyolipomas

⸻

Minor Diagnostic Features

Minor features include:

• Confetti skin lesions
• 3 dental enamel pits
• ≥2 intraoral fibromas
• Retinal achromic patch
• Multiple renal cysts
• Nonrenal hamartomas
• Selected sclerotic bone lesions

Criteria have evolved over time, so older “probable” and “suspect” categories should not be relied on without reference to current consensus definitions.

⸻

Important Modern Correction About Diagnostic Categories

Older classifications used:

• Definite
• Probable
• Suspect

Modern consensus criteria emphasize:

Definite or possible clinical diagnosis, together with molecular confirmation when available.

⸻

Initial Ophthalmic Assessment

A patient with known or suspected TSC should undergo:

• Visual acuity
• Pupillary examination
• Ocular alignment
• Dilated fundus examination
• Optic disc evaluation
• Retinal examination

Document retinal hamartomas with:

• Photography
• OCT when useful

⸻

Childhood Visual Development

Children should also be assessed for:

• Refractive error
• Strabismus
• Amblyopia

These common pediatric problems may impair vision more than the retinal hamartoma itself.

⸻

Treatment of Retinal Astrocytic Hamartomas

Most asymptomatic lesions require:

No ocular treatment.

Observation with serial examination and imaging is sufficient.

⸻

When Ocular Treatment Is Needed

Treatment may be considered if a lesion causes:

• Progressive exudation
• Macular edema
• Serous retinal detachment
• Vitreous hemorrhage
• Neovascular complications

Options may include:

• Anti-VEGF therapy
• Laser photocoagulation
• Photodynamic therapy in selected lesions
• Vitrectomy for traction or hemorrhage
• Systemic mTOR inhibition when indicated for broader TSC disease

⸻

mTOR Inhibitors and Retinal Lesions

Systemic:

• Everolimus
• Sirolimus

have occasionally been associated with reduction in size or activity of retinal astrocytic hamartomas.

However:

Asymptomatic stable retinal lesions do not require systemic mTOR treatment solely for the eye.

⸻

Treatment of Facial Angiofibromas

Modern treatment may include:

Topical sirolimus

which can substantially reduce facial angiofibroma severity.

Other options include:

• Laser
• Ablative therapy
• Dermatologic surgery

⸻

Treatment of SEGA

Growing or symptomatic SEGA may be treated with:

• Everolimus
• Neurosurgical resection

Choice depends on:

• Tumor growth
• Hydrocephalus
• Symptoms
• Surgical accessibility

⸻

Epilepsy Management

TSC-associated seizures may require:

• Vigabatrin
• Other antiseizure medications
• Ketogenic diet
• Epilepsy surgery
• Everolimus in selected drug-resistant focal seizures

Early seizure control is important for neurodevelopmental outcome.

⸻

Surveillance – Brain

Patients typically undergo periodic:

Brain MRI

during childhood and young adulthood to monitor for:

• SEGA
• Hydrocephalus
• New structural complications

Imaging intervals depend on:

• Age
• Existing lesions
• Symptoms

⸻

Surveillance – Kidneys

Renal surveillance generally includes:

• Periodic MRI of the abdomen
• Blood pressure monitoring
• Renal function testing

This continues into adulthood because renal complications may progress silently.

⸻

Surveillance – Lungs

Adult women should be evaluated for LAM with:

• Pulmonary history
• Lung-function testing when indicated
• High-resolution CT according to current surveillance guidance

Chest radiography alone is insufficiently sensitive.

⸻

Surveillance – Eyes

Regular ophthalmic review should assess:

• Retinal hamartoma stability
• Visual acuity
• Refractive error
• Strabismus
• Amblyopia
• Vigabatrin-associated retinal toxicity when relevant

Frequency is individualized.

⸻

Why Multidisciplinary Care Is Essential

Patients may require coordination among:

• Neurology
• Genetics
• Nephrology
• Pulmonology
• Cardiology
• Dermatology
• Psychiatry/developmental specialists
• Ophthalmology

TSC care is increasingly organized around:

Lifelong surveillance rather than treatment only when symptoms appear.

⸻

Genetic Counseling

Because inheritance is autosomal dominant, an affected individual has approximately a:

50% chance of transmitting the pathogenic variant to each child.

Options may include:

• Predictive testing
• Prenatal testing
• Preimplantation genetic testing

when the familial variant is known.

⸻

Expected Long-Term Course

Life expectancy may be near normal in mildly affected individuals.

More severe morbidity may result from:

• Epilepsy
• SEGA
• Renal disease
• LAM
• Neuropsychiatric complications

Modern surveillance and mTOR-targeted therapy have substantially changed management compared with older descriptions.

⸻

Major Ocular Prognostic Point

Most TSC-related retinal hamartomas:

Do not threaten vision.

Vision is most likely to be affected when there is:

• Macular involvement
• Optic disc involvement
• Exudation
• Retinal detachment
• Vitreous hemorrhage
• Associated amblyopia

⸻

High-Yield Takeaways

• Tuberous sclerosis complex is an autosomal dominant multisystem hamartoma syndrome caused by pathogenic variants in TSC1 or TSC2 with resulting mTORC1 overactivation.
• The historic Vogt triad of seizures, “adenoma sebaceum,” and intellectual disability is not required for diagnosis.
• The correct modern term for “adenoma sebaceum” is facial angiofibroma.
• Genetic testing is now reliable and clinically useful; the older statement that no reliable testing exists is obsolete.
• TSC1 encodes hamartin and TSC2 encodes tuberin.
• Major neurologic manifestations include cortical tubers, subependymal nodules, SEGA, epilepsy, and TAND.
• Vigabatrin is first-line therapy for TSC-associated infantile spasms, but prolonged exposure can cause irreversible visual-field loss.
• The classic ophthalmic lesion is the retinal astrocytic hamartoma, which may be flat, nodular, calcified, solitary, multiple, unilateral, or bilateral.
• Multiple bilateral retinal hamartomas strongly support TSC, but a solitary astrocytic hamartoma can occur without TSC.
• Most retinal hamartomas are stable and require observation only.
• Rare ocular complications include exudation, macular edema, retinal detachment, vitreous hemorrhage, and neovascularization.
• OCT and fundus photography are useful for documenting retinal lesions and monitoring change.
• Retinal achromic patches are a minor diagnostic feature.
• Cardiac rhabdomyomas are particularly important in fetuses and infants and often regress spontaneously.
• Renal angiomyolipomas and pulmonary LAM are major causes of systemic morbidity.
• Everolimus and sirolimus are now established mTOR-targeted therapies, not experimental agents.
• Everolimus may treat SEGA, renal angiomyolipoma, and selected TSC-associated seizures, while sirolimus is important in LAM and can be used topically for facial angiofibromas.
• Modern diagnosis is based on current clinical criteria and/or molecular confirmation, rather than the older “definite/probable/suspect” framework alone.
• Long-term care requires multidisciplinary surveillance of the brain, kidneys, lungs, heart, skin, development, and eyes.
• Ophthalmic prognosis is generally good because most retinal hamartomas remain asymptomatic and nonprogressive.

Important Modern Terminology The preferred name is: Tuberous sclerosis complex rather than simply “tuberous sclerosis.” The historic triad of:  Seizures “Adenoma sebaceum” Intellectual disability  is known as the Vogt triad, but it is: Neither sensitive nor required for diagnosis. Many patients do not have all three findings.

Important Modern Correction About Language Older descriptions used:  “Adenoma sebaceum” “Mental retardation”  Modern terminology is:  Facial angiofibromas Intellectual disability  Facial angiofibromas are neither adenomas nor sebaceous lesions.

Genetic Basis TSC results from pathogenic variants in:  TSC1 on chromosome 9 → encodes hamartin TSC2 on chromosome 16 → encodes tuberin  Hamartin and tuberin form a complex that normally suppresses: mTORC1 signaling. Loss of this inhibitory pathway produces excessive:  Cell growth Protein synthesis Proliferation Hamartoma formation

Why mTOR Is So Important The central molecular abnormality is: Overactivation of the mechanistic target of rapamycin pathway. This explains why: mTOR inhibitors such as everolimus and sirolimus now have established therapeutic roles in TSC.

Inheritance Pattern TSC is: Autosomal dominant with variable expression. However, a large proportion of affected individuals represent: De novo pathogenic variants and therefore have no affected parent.

Genetic Testing – Major Modern Correction Older sources stated that reliable genetic testing was unavailable. This is now incorrect. Modern molecular testing can identify a pathogenic variant in: TSC1 or TSC2 in most patients with clinically definite TSC. Genetic testing is useful for:  Confirming diagnosis Family counseling Testing at-risk relatives Prenatal or reproductive counseling  A negative genetic test does not completely exclude TSC because mosaic or difficult-to-detect variants can occur.

Who Develops It TSC occurs in all ethnic groups and both sexes. Estimated birth incidence is roughly: 1 in 6,000–10,000 live births although prevalence estimates vary. Clinical severity ranges from:  Very mild disease discovered incidentally Severe neurologic, renal, pulmonary, or developmental disease

Why the Phenotype Is So Variable Even individuals within the same family may have very different manifestations. Variation results from:  Different pathogenic variants Mosaicism Second-hit somatic mutations Other genetic and environmental modifiers  Therefore genotype does not perfectly predict clinical severity.

Major Organ Systems Involved TSC most commonly affects:  Central nervous system Skin Kidneys Heart Lungs Retina Teeth/oral cavity Bone  It is therefore fundamentally a: Multidisciplinary disease.

Neurologic Manifestations Major neurologic abnormalities include:  Cortical tubers Subependymal nodules Subependymal giant cell astrocytoma Epilepsy Infantile spasms Neurodevelopmental disorders  Seizures are among the most common and clinically important manifestations.

Cortical Tubers Cortical and subcortical tubers are areas of:  Abnormal cortical development Dysplastic neurons Giant cells Gliosis  They are strongly associated with: Epilepsy and neurodevelopmental impairment.

Subependymal Nodules Subependymal nodules occur along the walls of the lateral ventricles. They may:  Calcify Remain stable Occasionally evolve into or coexist with a subependymal giant cell astrocytoma (SEGA)

Subependymal Giant Cell Astrocytoma SEGA typically develops near the: Foramen of Monro and can obstruct cerebrospinal fluid flow. Potential consequences include:  Hydrocephalus Headache Vomiting Papilledema Behavioral change Reduced consciousness

Ocular Relevance of Raised Intracranial Pressure A patient with TSC and SEGA may develop: Papilledema if obstructive hydrocephalus occurs. Papilledema in TSC is therefore usually a consequence of intracranial pressure, not a primary retinal manifestation.

Infantile Spasms Infantile spasms are particularly important in TSC. They may present with:  Brief flexor spasms Extensor spasms Head nodding Clusters of repetitive movements  They require: Prompt neurologic treatment.

First-Line Treatment of Infantile Spasms In TSC-associated infantile spasms: Vigabatrin is generally first-line therapy. This is a major modern management point.

Ophthalmic Relevance of Vigabatrin Vigabatrin can cause: Permanent concentric visual-field loss through retinal toxicity. Risk relates particularly to:  Cumulative exposure Duration of therapy  Children receiving vigabatrin require age-appropriate ophthalmic monitoring when feasible.

TSC-Associated Neuropsychiatric Disorders The umbrella term: TAND – TSC-associated neuropsychiatric disorders includes:  Intellectual disability Autism spectrum disorder ADHD Anxiety Mood disorders Behavioral difficulties Sleep problems Learning disorders  These manifestations are common but highly variable.

Characteristic Skin Findings Cutaneous findings are often important diagnostic clues. They include:  Hypomelanotic macules Facial angiofibromas Shagreen patch Ungual/periungual fibromas Confetti skin lesions

Hypomelanotic Macules These are often called: Ash-leaf macules because of their shape. They may be present: At birth or early infancy and are often easier to detect with: Wood lamp examination.

Facial Angiofibromas Facial angiofibromas are:  Reddish papules Frequently distributed over the nose and central face Often appearing during childhood  They were historically called: Adenoma sebaceum, an outdated term.

Shagreen Patch A shagreen patch is:  Thickened Leathery Connective-tissue nevus-like plaque  often located over the: Lumbosacral region.

Ungual Fibromas Periungual or subungual fibromas:  Develop around nails Are more common later in childhood or adulthood  These are also called: Koenen tumors.

Major Ocular Manifestation The classic eye lesion in TSC is: Retinal astrocytic hamartoma. These lesions may occur:  On the optic disc Adjacent to the disc In the peripheral retina  They can be:  Solitary Multiple Unilateral Bilateral  Multiple bilateral lesions strongly support TSC.

Retinal Astrocytic Hamartoma – Clinical Appearance These lesions may appear as:  Flat translucent retinal thickening Gray-white nodules Calcified “mulberry-like” masses  They often arise from the: Retinal nerve fiber layer.

Traditional Morphologic Patterns Three classic appearances are described: Type 1 Relatively flat, smooth, semitranslucent lesion. Type 2 Calcified, nodular: “Mulberry” lesion Type 3 Mixed characteristics. These patterns may represent stages along a morphologic spectrum.

Optic Disc Involvement Astrocytic hamartomas may arise:  On the optic nerve head Immediately adjacent to it  They can resemble:  Optic disc drusen Papilledema Other calcified lesions  Multimodal imaging helps clarify the diagnosis.

Optical Coherence Tomography OCT may demonstrate:  Hyperreflective retinal mass Distortion of retinal layers Calcification-related shadowing Intraretinal cystic change in exudative lesions  OCT is useful for:  Baseline documentation Monitoring growth Detecting associated fluid

Fundus Autofluorescence Calcified astrocytic hamartomas may demonstrate: Hyperautofluorescence although appearance varies according to:  Calcification Pigment Overlying retina

B-Scan Ultrasonography Larger calcified lesions may show:  High internal reflectivity Acoustic shadowing  This can help distinguish heavily calcified hamartomas from other retinal masses.

Fluorescein Angiography FA may show:  Intrinsic tumor vasculature Late staining Leakage in more active or exudative lesions  Routine FA is unnecessary for asymptomatic stable lesions.

Retinal Hypopigmented Lesions Some patients have: Retinal achromic patches which appear as hypopigmented retinal or RPE lesions. These are recognized as a: Minor diagnostic feature in modern criteria.

Are Retinal Hamartomas Usually Dangerous? Most retinal astrocytic hamartomas are: Stable and asymptomatic. They often require: Observation only.

Rare Ocular Complications Occasionally, retinal astrocytic hamartomas may produce:  Exudation Macular edema Serous retinal detachment Vitreous hemorrhage Retinal neovascularization Fibrosis Secondary glaucoma  Severe progressive ocular disease is uncommon.

Can Retinal Hamartomas Grow? Yes, but substantial progression is uncommon. Some lesions may:  Slowly enlarge Become more calcified Develop exudation  Serial photography and OCT are useful when growth is uncertain.

Differential Diagnosis of Retinal Astrocytic Hamartoma Important mimics include:  Retinoblastoma Optic disc drusen Solitary retinal astrocytic hamartoma Myelinated retinal nerve fibers Toxocariasis Coats disease Other calcified retinal lesions

Distinguishing It From Retinoblastoma This is particularly important in young children. Retinoblastoma more commonly shows:  True intraocular tumor mass Prominent calcification Subretinal or vitreous seeds Progressive growth Retinal detachment  TSC-associated astrocytic hamartomas are usually:  Surface retinal lesions Relatively stable Often multiple or bilateral Associated with other TSC features

Solitary Retinal Astrocytic Hamartoma An isolated retinal astrocytic hamartoma may occur in a patient without TSC. Therefore: One retinal astrocytic hamartoma does not automatically diagnose tuberous sclerosis complex. The systemic context matters.

Cardiac Manifestations The classic cardiac lesion is: Rhabdomyoma. These are often detected:  Prenatally During infancy  They may cause:  Arrhythmia Obstruction Heart failure  Many regress spontaneously during childhood.

Why Cardiac Rhabdomyoma Is a Diagnostic Clue Multiple fetal or neonatal cardiac rhabdomyomas are strongly associated with: TSC and may prompt genetic evaluation before other manifestations become apparent.

Renal Manifestations Major renal abnormalities include:  Angiomyolipomas Renal cysts Chronic kidney disease  Rarely:  Renal cell carcinoma  Renal disease is a major determinant of long-term morbidity.

Renal Angiomyolipoma Angiomyolipomas consist of varying proportions of:  Blood vessels Smooth muscle Fat  Large lesions may cause:  Hemorrhage Flank pain Hematuria Renal impairment

Modern Treatment of Renal Angiomyolipoma For enlarging or clinically significant TSC-associated angiomyolipoma: mTOR inhibition with everolimus is now an established treatment option. Selective embolization is preferred for: Acute hemorrhage. Nephron-sparing approaches are favored whenever possible.

Pulmonary Manifestations The major pulmonary complication is: Lymphangioleiomyomatosis (LAM). It occurs predominantly in: Women after puberty.

Lymphangioleiomyomatosis LAM produces abnormal proliferation of smooth-muscle-like cells leading to:  Pulmonary cysts Dyspnea Pneumothorax Chylous effusion Progressive loss of lung function  Chest CT is much more sensitive than chest radiography.

Modern Treatment of LAM Clinically significant LAM may be treated with: Sirolimus which can stabilize or improve pulmonary function. Lung transplantation is reserved for severe end-stage disease.

Oral Findings Oral manifestations may include:  Dental enamel pits Gingival fibromas  These can support the diagnosis.

Bone Findings Sclerotic bone lesions may occur, particularly in:  Spine Pelvis Skull  They are often asymptomatic and usually do not require treatment.

Modern Diagnostic Framework TSC is diagnosed using:  Clinical criteria Molecular genetic criteria  A pathogenic variant in: TSC1 or TSC2 can establish a molecular diagnosis.

Definite Clinical Diagnosis A definite clinical diagnosis generally requires: Two major features or: One major feature plus at least two minor features. This basic structure remains clinically useful.

Major Diagnostic Features Major features include:  ≥3 hypomelanotic macules ≥3 facial angiofibromas or fibrous cephalic plaque ≥2 ungual fibromas Shagreen patch Multiple retinal hamartomas Cortical dysplasias ≥2 subependymal nodules SEGA Cardiac rhabdomyoma LAM ≥2 renal angiomyolipomas

Minor Diagnostic Features Minor features include:  Confetti skin lesions 3 dental enamel pits ≥2 intraoral fibromas Retinal achromic patch Multiple renal cysts Nonrenal hamartomas Selected sclerotic bone lesions  Criteria have evolved over time, so older “probable” and “suspect” categories should not be relied on without reference to current consensus definitions.

Important Modern Correction About Diagnostic Categories Older classifications used:  Definite Probable Suspect  Modern consensus criteria emphasize: Definite or possible clinical diagnosis, together with molecular confirmation when available.

Initial Ophthalmic Assessment A patient with known or suspected TSC should undergo:  Visual acuity Pupillary examination Ocular alignment Dilated fundus examination Optic disc evaluation Retinal examination  Document retinal hamartomas with:  Photography OCT when useful

Childhood Visual Development Children should also be assessed for:  Refractive error Strabismus Amblyopia  These common pediatric problems may impair vision more than the retinal hamartoma itself.

Treatment of Retinal Astrocytic Hamartomas Most asymptomatic lesions require: No ocular treatment. Observation with serial examination and imaging is sufficient.

When Ocular Treatment Is Needed Treatment may be considered if a lesion causes:  Progressive exudation Macular edema Serous retinal detachment Vitreous hemorrhage Neovascular complications  Options may include:  Anti-VEGF therapy Laser photocoagulation Photodynamic therapy in selected lesions Vitrectomy for traction or hemorrhage Systemic mTOR inhibition when indicated for broader TSC disease

mTOR Inhibitors and Retinal Lesions Systemic:  Everolimus Sirolimus  have occasionally been associated with reduction in size or activity of retinal astrocytic hamartomas. However: Asymptomatic stable retinal lesions do not require systemic mTOR treatment solely for the eye.

Treatment of Facial Angiofibromas Modern treatment may include: Topical sirolimus which can substantially reduce facial angiofibroma severity. Other options include:  Laser Ablative therapy Dermatologic surgery

Treatment of SEGA Growing or symptomatic SEGA may be treated with:  Everolimus Neurosurgical resection  Choice depends on:  Tumor growth Hydrocephalus Symptoms Surgical accessibility

Epilepsy Management TSC-associated seizures may require:  Vigabatrin Other antiseizure medications Ketogenic diet Epilepsy surgery Everolimus in selected drug-resistant focal seizures  Early seizure control is important for neurodevelopmental outcome.

Surveillance – Brain Patients typically undergo periodic: Brain MRI during childhood and young adulthood to monitor for:  SEGA Hydrocephalus New structural complications  Imaging intervals depend on:  Age Existing lesions Symptoms

Surveillance – Kidneys Renal surveillance generally includes:  Periodic MRI of the abdomen Blood pressure monitoring Renal function testing  This continues into adulthood because renal complications may progress silently.

Surveillance – Lungs Adult women should be evaluated for LAM with:  Pulmonary history Lung-function testing when indicated High-resolution CT according to current surveillance guidance  Chest radiography alone is insufficiently sensitive.

Surveillance – Eyes Regular ophthalmic review should assess:  Retinal hamartoma stability Visual acuity Refractive error Strabismus Amblyopia Vigabatrin-associated retinal toxicity when relevant  Frequency is individualized.

Why Multidisciplinary Care Is Essential Patients may require coordination among:  Neurology Genetics Nephrology Pulmonology Cardiology Dermatology Psychiatry/developmental specialists Ophthalmology  TSC care is increasingly organized around: Lifelong surveillance rather than treatment only when symptoms appear.

Genetic Counseling Because inheritance is autosomal dominant, an affected individual has approximately a: 50% chance of transmitting the pathogenic variant to each child. Options may include:  Predictive testing Prenatal testing Preimplantation genetic testing  when the familial variant is known.

Expected Long-Term Course Life expectancy may be near normal in mildly affected individuals. More severe morbidity may result from:  Epilepsy SEGA Renal disease LAM Neuropsychiatric complications  Modern surveillance and mTOR-targeted therapy have substantially changed management compared with older descriptions.

Major Ocular Prognostic Point Most TSC-related retinal hamartomas: Do not threaten vision. Vision is most likely to be affected when there is:  Macular involvement Optic disc involvement Exudation Retinal detachment Vitreous hemorrhage Associated amblyopia

High-Yield Takeaways  Tuberous sclerosis complex is an autosomal dominant multisystem hamartoma syndrome caused by pathogenic variants in TSC1 or TSC2 with resulting mTORC1 overactivation. The historic Vogt triad of seizures, “adenoma sebaceum,” and intellectual disability is not required for diagnosis. The correct modern term for “adenoma sebaceum” is facial angiofibroma. Genetic testing is now reliable and clinically useful; the older statement that no reliable testing exists is obsolete. TSC1 encodes hamartin and TSC2 encodes tuberin. Major neurologic manifestations include cortical tubers, subependymal nodules, SEGA, epilepsy, and TAND. Vigabatrin is first-line therapy for TSC-associated infantile spasms, but prolonged exposure can cause irreversible visual-field loss. The classic ophthalmic lesion is the retinal astrocytic hamartoma, which may be flat, nodular, calcified, solitary, multiple, unilateral, or bilateral. Multiple bilateral retinal hamartomas strongly support TSC, but a solitary astrocytic hamartoma can occur without TSC. Most retinal hamartomas are stable and require observation only. Rare ocular complications include exudation, macular edema, retinal detachment, vitreous hemorrhage, and neovascularization. OCT and fundus photography are useful for documenting retinal lesions and monitoring change. Retinal achromic patches are a minor diagnostic feature. Cardiac rhabdomyomas are particularly important in fetuses and infants and often regress spontaneously. Renal angiomyolipomas and pulmonary LAM are major causes of systemic morbidity. Everolimus and sirolimus are now established mTOR-targeted therapies, not experimental agents. Everolimus may treat SEGA, renal angiomyolipoma, and selected TSC-associated seizures, while sirolimus is important in LAM and can be used topically for facial angiofibromas. Modern diagnosis is based on current clinical criteria and/or molecular confirmation, rather than the older “definite/probable/suspect” framework alone. Long-term care requires multidisciplinary surveillance of the brain, kidneys, lungs, heart, skin, development, and eyes. Ophthalmic prognosis is generally good because most retinal hamartomas remain asymptomatic and nonprogressive.